Androgen Decline in the Aging Male: Making Sense of the “Male Menopause”

  • Daniel A. ShoskesEmail author
Part of the Current Clinical Urology book series (CCU)


Testosterone often declines as men age, and this decline may be associated with a number of specific physical changes that affect quality of life and life expectancy. Unlike the female menopause, which is rapid and well described, this “male menopause” may be gradual, and discerning symptoms that are actually caused by testosterone deficiency and improved by testosterone replacement can be challenging. This chapter will review Androgen Decline in the Aging Male (ADAM), also known as Testosterone Deficiency Syndrome (TDS) and cover symptoms, diagnosis, treatment options, and precautions.


Prostate Cancer Erectile Dysfunction Testosterone Level Serum Testosterone Free Testosterone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Simon D, Preziosi P, Barrett-Connor E, et al. The influence of aging on plasma sex hormones in men: the Telecom Study. Am J Epidemiol. 1992;135:783–91.PubMedGoogle Scholar
  2. 2.
    Araujo AB, O’Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Travison TG, Shackelton R, Araujo AB, et al. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc. 2008;56:831–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95:1810–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33:1186–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Haring R, Ittermann T, Volzke H, et al. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. Aging Male. 2010;13:247–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26(1):184–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166:1660–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Carrero JJ, Qureshi AR, Parini P, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol. 2009;20:613–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J. 2010;31:1494–501.PubMedCrossRefGoogle Scholar
  12. 12.
    Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007–19.PubMedCrossRefGoogle Scholar
  13. 13.
    Saha MT, Saha HH, Niskanen LK, Salmela KT, Pasternack AI. Time course of serum prolactin and sex hormones following successful renal transplantation. Nephron. 2002;92:735–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf). 2010;73:382–8.CrossRefGoogle Scholar
  15. 15.
    Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35.PubMedCrossRefGoogle Scholar
  16. 16.
    Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004;89:3813–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Joshi D, van Schoor NM, de Ronde W, et al. Low free testosterone levels are associated with prevalence and incidence of depressive symptoms in older men. Clin Endocrinol (Oxf). 2010;72:232–40.CrossRefGoogle Scholar
  18. 18.
    Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46:80–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010;7:269–76.PubMedCrossRefGoogle Scholar
  21. 21.
    Cavender RK, Fairall M. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis. J Sex Med. 2009;6:3177–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009;55:121–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl. 2002;23:922–6.PubMedGoogle Scholar
  24. 24.
    Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560–75.PubMedCrossRefGoogle Scholar
  25. 25.
    Hanafy HM. Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med. 2007;4:1241–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7:3495–503.PubMedCrossRefGoogle Scholar
  27. 27.
    Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.PubMedCrossRefGoogle Scholar
  28. 28.
    Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165(5):687–701.PubMedCrossRefGoogle Scholar
  29. 29.
    Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011;8(11):3204–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8:284–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Rhoden EL, Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med. 2010;7:277–83.PubMedCrossRefGoogle Scholar
  32. 32.
    Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–22.PubMedCrossRefGoogle Scholar
  33. 33.
    Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Botto H, Neuzillet Y, Lebret T, Camparo P, Molinie V, Raynaud JP. High incidence of predominant gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol. 2011;186:1400–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Salonia A, Gallina A, Briganti A, et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer. 2011;117:3953–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Khera M. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med. 2009;6 Suppl 3:234–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536–41.PubMedCrossRefGoogle Scholar
  38. 38.
    Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila DJ, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185:1256–60.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of UrologyThe Glickman Urologic and Kidney Institute, Cleveland ClinicClevelandUSA

Personalised recommendations